NEW YORK, Feb. 11 (GenomeWeb News) - Keith Olson has left Guava Technologies, according to Inside Bioassays, a GenomeWeb newsletter. He used to be the company's director of product commercialization. Olson has taken a position with Fremont, Calif.-based drug discovery firm DiscoverX.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.